Plain-English translation of NCT07647172 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is observing how well a medication called micronized purified flavonoid fraction (MPFF) works for people recovering from minimally invasive hemorrhoid surgery. Rather than testing a brand-new treatment, researchers are watching real-world patients and comparing those who receive this medication after surgery with those who don't, to see how it affects healing, symptoms, and quality of life.
Hemorrhoid surgery can be painful and have complications during recovery. Doctors want to understand whether this medication—which may help with blood vessel health—truly improves healing and patient satisfaction when added to standard care after surgery.
You likely qualify if…
You likely don't qualify if…
You will have your scheduled minimally invasive surgery as planned with your doctor. After surgery, depending on which clinic enrolls you, you may receive the flavonoid medication or standard care without it. Researchers will track your recovery using standard medical exams and will ask you about your symptoms, pain levels, and satisfaction with treatment—all routine questions your doctor would normally ask. The study follows how well you heal over the recovery period.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
Russia
Sponsor
Servier Russia
Enrollment target
~200 participants
Started
June 2026
Primary completion
November 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
OLGA LINNIK
A.N. Ryzhikh National Medical Research Center of Proctology
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.